Biomarin Pharmaceutical Stock Market Value
| BMRN Stock | USD 69.07 0.26 0.38% |
| Symbol | Biomarin |
Biomarin Pharmaceutical Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 6.449 | Earnings Share 2.13 | Revenue Per Share | Quarterly Revenue Growth 0.156 | Return On Assets |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Biomarin Pharmaceutical 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Biomarin Pharmaceutical's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Biomarin Pharmaceutical.
| 01/28/2025 |
| 02/27/2025 |
If you would invest 0.00 in Biomarin Pharmaceutical on January 28, 2025 and sell it all today you would earn a total of 0.00 from holding Biomarin Pharmaceutical or generate 0.0% return on investment in Biomarin Pharmaceutical over 30 days. Biomarin Pharmaceutical is related to or competes with Alnylam Pharmaceuticals, Exelixis, Halozyme Therapeutics, Arrowhead Pharmaceuticals, Incyte, Ionis Pharmaceuticals, and Apellis Pharmaceuticals. BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare dis... More
Biomarin Pharmaceutical Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Biomarin Pharmaceutical's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Biomarin Pharmaceutical upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.93 | |||
| Information Ratio | 0.0973 | |||
| Maximum Drawdown | 10.0 | |||
| Value At Risk | (3.32) | |||
| Potential Upside | 3.13 |
Biomarin Pharmaceutical Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biomarin Pharmaceutical's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Biomarin Pharmaceutical's standard deviation. In reality, there are many statistical measures that can use Biomarin Pharmaceutical historical prices to predict the future Biomarin Pharmaceutical's volatility.| Risk Adjusted Performance | 0.0789 | |||
| Jensen Alpha | 0.1625 | |||
| Total Risk Alpha | 0.1792 | |||
| Sortino Ratio | 0.0883 | |||
| Treynor Ratio | (0.79) |
Biomarin Pharmaceutical Backtested Returns
As of now, Biomarin Stock is very steady. Biomarin Pharmaceutical secures Sharpe Ratio (or Efficiency) of 0.0473, which signifies that the company had a 0.0473 % return per unit of risk over the last 3 months. We have found thirty technical indicators for Biomarin Pharmaceutical, which you can use to evaluate the volatility of the firm. Please confirm Biomarin Pharmaceutical's Risk Adjusted Performance of 0.0789, downside deviation of 1.93, and Mean Deviation of 1.23 to double-check if the risk estimate we provide is consistent with the expected return of 0.0862%. Biomarin Pharmaceutical has a performance score of 3 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.21, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Biomarin Pharmaceutical are expected to decrease at a much lower rate. During the bear market, Biomarin Pharmaceutical is likely to outperform the market. Biomarin Pharmaceutical right now shows a risk of 1.82%. Please confirm Biomarin Pharmaceutical semi variance, and the relationship between the treynor ratio and daily balance of power , to decide if Biomarin Pharmaceutical will be following its price patterns.
Auto-correlation | 0.36 |
Below average predictability
Biomarin Pharmaceutical has below average predictability. Overlapping area represents the amount of predictability between Biomarin Pharmaceutical time series from 28th of January 2025 to 12th of February 2025 and 12th of February 2025 to 27th of February 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Biomarin Pharmaceutical price movement. The serial correlation of 0.36 indicates that just about 36.0% of current Biomarin Pharmaceutical price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.36 | |
| Spearman Rank Test | 0.41 | |
| Residual Average | 0.0 | |
| Price Variance | 4.68 |
Biomarin Pharmaceutical lagged returns against current returns
Autocorrelation, which is Biomarin Pharmaceutical stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Biomarin Pharmaceutical's stock expected returns. We can calculate the autocorrelation of Biomarin Pharmaceutical returns to help us make a trade decision. For example, suppose you find that Biomarin Pharmaceutical has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Biomarin Pharmaceutical regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Biomarin Pharmaceutical stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Biomarin Pharmaceutical stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Biomarin Pharmaceutical stock over time.
Current vs Lagged Prices |
| Timeline |
Biomarin Pharmaceutical Lagged Returns
When evaluating Biomarin Pharmaceutical's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Biomarin Pharmaceutical stock have on its future price. Biomarin Pharmaceutical autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Biomarin Pharmaceutical autocorrelation shows the relationship between Biomarin Pharmaceutical stock current value and its past values and can show if there is a momentum factor associated with investing in Biomarin Pharmaceutical.
Regressed Prices |
| Timeline |
When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock:
Check out Biomarin Pharmaceutical Correlation, Biomarin Pharmaceutical Volatility and Biomarin Pharmaceutical Alpha and Beta module to complement your research on Biomarin Pharmaceutical. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Biomarin Pharmaceutical technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.